Home > Press > Nanophase Announces Fourth Quarter and 2007 Results
Abstract:
21% Fourth Quarter Revenue Growth; 36% Annual Revenue Growth
For the quarter ending December 31, 2007, total revenue was $2.62 million compared to $2.17 million for the fourth quarter of 2006, representing a 21% revenue increase year-over-year (YOY) and the highest fourth quarter revenue in the Company's history. Nanophase reported a fourth quarter 2007 net loss of $1.16 million, or $0.06 per share, compared with a net loss for the 2006 fourth quarter of $1.6M million, or $0.08 per share.
For the year ended December 31, 2007, Nanophase's revenue increased to $12.21 million, compared to $8.99 million in 2006, representing total revenue growth of 36% YOY. During 2007, gross margin on sales increased to 26% of revenue, versus 22% in 2006, due to increased volume. Nanophase reported a 2007 net loss of $3.59 million, or $0.18 per share, compared with a net loss of $5.18 million, or $0.28 per share in 2006. For 2007 cash used for operations totaled $1.6 million, which was a 50% reduction or improvement from $3.2 million during 2006, reflecting increased volume and higher gross margins. Ending 2007, Nanophase noted that it had $16.7 million in cash and equivalents, which management deems to be more than adequate to fund the Company over its planning horizon.
"2007 was another solid year of revenue growth, gross margin expansion, and technical progress," noted Joseph Cross, Nanophase's President and CEO. "Each of these measures is a key focal point for the Company and has seen consistent material improvement over the last three years. Beginning in 2005, revenue has grown over 30% each year and gross margins have now almost doubled in the last 24 months. As our business model predicts and growth has demonstrated, increasing volume with a relatively fixed overhead cost results in higher gross product margins."
"Nanophase is increasingly focused on developing and delivering ready-to-use nanomaterial solutions to customers and target markets. Due to our novel ability to incorporate nanomaterials into customer-specific formulations with engineered dispersions, we have been able to add increased value to nanomaterial products, which has generated new business opportunities and led to revenue growth." Cross noted during 2007 most of the Company's key market segments experienced growth. Personal care product volume increased more than 10% year-over-year, revenue for industrial coatings increased over 500%, and architectural coating product volume increased over 50%.
Cross noted that the Company had implemented initiatives to improve sales and marketing during 2007 by hiring Kevin Wenta, as EVP of Sales and Marketing, and David Nelson as Vice President of Sales -- both with excellent experience in chemical sales. Throughout 2007, Nanophase has been improving its sales processes and honing application development to increase the Company's depth of understanding in focus applications and markets. "The increased understanding and direct application testing allows Nanophase to approach a market or customer opportunity with clear data on the value and performance of nanomaterials for their particular products," stated Cross. "We anticipate that increased application development should increase our sales success and reduce the time-to-market." Nanophase plans to add to its sales and marketing staff during 2008 to allow the Company to directly sell into additional markets.
Summary 2007 Highlights
1. Intellectual property: Nanophase received two US patents during 2007,
and owns or licenses 18 United States and 49 foreign patents and
patent applications. Additionally, Nanophase has accumulated
considerable proprietary process and application knowledge that the
Company believes provides significant market(s) advantages.
2. Introduced innovative nanoengineered products for water-based
formulations, including printed electronics, antimicrobials, and
architectural coatings. For example in architectural coatings the
nanoengineered products typically improve the scratch and mar
resistance of the coating by more than 300% while retaining high
gloss. These new coating products will be sold globally through
Nanophase's market partner, BYK Chemie; other applications will be
marketed and sold directly by Nanophase.
3. Recertified the Company's facilities and processes to ISO9001:2000,
the internationally recognized standard of manufacturing and quality
excellence, and ISO14001:2004, the international environmental
management standard.
4. Achieved 99.1% Customer Service Level on product shipments and, again,
had NO customer quality returns.
5. Nanophase employees reached a new safety record achieving 850,000
continuous working hours without a lost time accident.
6. As a responsible corporate citizen, Nanophase continued to operate all
manufacturing facilities in compliance with State and Federal
hazardous waste (RCCA), air emissions, and wastewater permits, while
meeting or exceeding applicable OSHA, TSCA, and hazardous materials
requirements.
Markets and Outlook
Nanophase expects continuing revenue growth despite some specific changes compared to 2007 revenue. Cross noted that the Company invoked customer surcharges for certain products to cover the dramatic increase in commodity (raw material) costs experienced during the last half of 2006, which were part of the product pricing during 2007. Recently, commodity costs have significantly moderated and Nanophase has reduced surcharges accordingly. At today's price levels, Nanophase would have had approximately $500,000 less in surcharge revenue during 2007. "While surcharges increased revenue during 2007, as they are applied as a billing adder, in some cases they also reduce product margins when we are not fully able to recover escalated underlying material costs," Cross stated. "So, while revenues can be reduced when commodity prices go down, gross margin, in both dollar and percentage terms, actually may increase."
Entering 2008, the Company has limited visibility regarding the possible impact of current market and economic conditions, particularly the decline in new housing, on demand for architectural and flooring products. Cross noted that revenue for both of these markets has been expanding over the past 24 months, but principally during 2007, aided in part by demand required to initially stock retail locations. Nanophase expects appreciable growth in electronics, primarily nanomaterials for CMP, and has received purchase orders and delivery schedules for $1.3 million during 2008, or about 70% growth over 2007. The Company also expects growth in sunscreens and personal care products during 2008, mainly during the second half as new EU UV regulations are predicted to increase usage for UVA protection.
For 2008, the Company estimates revenue growth of 5% to 15%. Cross noted that on a year-over-year comparison to 2007, based on current customer forecasts, the Company expects lower revenues during the first half of 2008 followed by growth during the second half. Cross stated "Current economic uncertainty in some of our markets (particularly architectural coatings), inventory builds during the first half of 2007, and the need to make-up 2007 commodity surcharge revenue, leads us to expect modest growth for 2008. We are watching the first quarter closely given this uncertainty, but anticipate lower revenues in the first half of 2008 followed by increased revenue run rate in the second half."
Nanophase has scheduled its quarterly conference call for February 7, 2008 at 4:00PM CST (5:00PM EST), which will be hosted by Joseph Cross, president and CEO, and Jess Jankowski, CFO. The call may be accessed through the Company's website, www.nanophase.com, and clicking on the link under Investor Relations and Calendar of Events. If you are unable to attend, a replay will be available through February 14, 2008 by dialing 706-645-9291 and entering code 32772211, or by logging onto the Company's website and following the above directions.
####
About Nanophase Technologies
Nanophase Technologies Corporation (NANX), www.nanophase.com, is a leader in nanomaterials technologies and provides nanoengineered solutions for multiple industrial product applications. Using a platform of patented and proprietary integrated nanomaterial technologies, the Company creates products with unique performance attributes from two ISO 9001:2000 and ISO 14001 facilities. Nanophase delivers commercial quantity and quality nanoparticles, coated nanoparticles, and nanoparticle dispersions in a variety of media. The Company owns or licenses 18 United States and 49 foreign patents and patent applications. Information about Nanophase may be found in the Company's public filings or on its website.
This press release contains words such as "expects", "shall", "will" , "believes" and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risk and uncertainties include the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company's dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company's nanocrystalline materials; the Company's manufacturing capacity and product mix flexibility in light of customer demand; the Company's limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company's dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; and other risks described in the Company's Form 10K filed March 14, 2007, and other filings with the Securities and Exchange Commission. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
NANOPHASE TECHNOLOGIES CORPORATION
BALANCE SHEETS
As of December 31,
2007 2006
ASSETS
Current assets:
Cash and cash equivalents $ 563,075 $ 132,387
Investments 16,145,844 8,434,793
Trade accounts receivable, less
allowance for doubtful accounts
of $13,000 and $22,000 on
December 31, 2007 and 2006,
respectively 1,403,206 1,459,391
Inventories, net 1,085,364 923,223
Prepaid expenses and other current
assets 298,464 534,407
Total current assets 19,495,953 11,484,201
Equipment and leasehold improvements,
net 7,409,666 7,608,326
Other assets, net 781,266 651,218
$ 27,686,885 $ 19,743,745
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debts $ - $ -
Current portion of capital lease
obligations 43,110 32,972
Current portion of deferred other
revenue 127,273 127,273
Accounts payable 238,295 478,694
Accrued expenses 1,584,656 1,643,585
Total current liabilities 1,993,334 2,282,524
Long-term debt, less current
maturities and unamortized debt
discount 1,512,507 1,383,707
Long-term portion of capital lease
obligations 31,430 50,552
Deferred other revenue, less
current portion 74,243 201,515
1,618,180 1,635,774
Contingent liabilities: - -
Stockholders' equity:
Preferred stock, $.01 par value;
24,088 authorized and no shares
issued and outstanding - -
Common stock, $.01 par value;
30,000,000 shares authorized;
21,088,068 and 18,995,581 shares
issued and outstanding on
December 31, 2007 and
December 31, 2006, respectively 210,881 189,956
Additional paid-in capital 90,201,131 78,380,962
Accumulated deficit (66,336,641) (62,745,471)
Total stockholders' equity 24,075,371 15,825,447
$ 27,686,885 $ 19,743,745
NANOPHASE TECHNOLOGIES CORPORATION
STATEMENTS OF OPERATIONS
Years ended December 31,
2007 2006 2005
Revenue:
Product revenue $11,766,565 $ 8,612,705 $ 6,444,444
Other revenue 442,543 378,133 357,463
Total revenue 12,209,108 8,990,838 6,801,907
Operating expense:
Cost of revenue 9,032,187 7,057,707 5,827,719
Gross Profit 3,176,921 1,933,131 974,188
Research and development expense 1,773,565 2,127,862 1,934,528
Selling, general and
administrative expense 5,427,863 5,302,836 4,422,011
Lease accounting adjustment - - 279,810
Loss from operations (4,024,507) (5,497,567) (5,662,161)
Interest income 661,512 366,701 295,935
Interest expense (154,515) (52,469) (50,273)
Other, net (73,660) 5,505 32,888
Loss before provision for income
taxes (3,591,170) (5,177,830) (5,383,611)
Provision for income taxes - - -
Net loss $(3,591,170) $(5,177,830) $(5,383,611)
Net loss per share-basic and
diluted $ (0.18) $ (0.28) $ (0.30)
Weighted average number of common
shares outstanding 20,038,868 18,344,334 17,937,932
NANOPHASE TECHNOLOGIES CORPORATION
STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
Years ended December 31,
2007 2006 2005
Revenue:
Product revenue $11,766,565 $ 8,612,705 $ 6,444,444
Other revenue 442,543 378,133 357,463
Total revenue 12,209,108 8,990,838 6,801,907
Operating expense:
Cost of revenue detail:
Depreciation 1,106,242 951,899 882,867
Non-cash equity compensation 45,144 34,805 4,935
Other costs of revenue 7,880,801 6,071,003 4,939,917
Cost of revenue 9,032,187 7,057,707 5,827,719
Gross Profit 3,176,921 1,933,131 974,188
Research and development expense
detail:
Depreciation 232,180 246,261 259,627
Non-cash equity compensation 92,831 133,507 23,953
Other research and development
expense 1,448,554 1,748,094 1,650,948
Research and development
expense 1,773,565 2,127,862 1,934,528
Selling, general and
administrative expense detail:
Depreciation and amortization 82,838 71,559 86,021
Non-cash equity compensation 435,430 476,898 44,421
Write-down of equipment 75,152 - -
Patent Abandonment - 149,811 -
Lease accounting adjustment - - 279,810
Other selling, general and
administrative expense 4,834,443 4,604,568 4,291,569
Selling, general and
administrative expense 5,427,863 5,302,836 4,701,821
Loss from operations (4,024,507) (5,497,567) (5,662,161)
Interest income 661,512 366,701 295,935
Interest expense (154,515) (52,469) (50,273)
Other, net (73,660) 5,505 32,888
Loss before provision for income
taxes (3,591,170) (5,177,830) (5,383,611)
Provision for income taxes - - -
Net loss $(3,591,170) $(5,177,830) $(5,383,611)
For more information, please click here
Contacts:
Nanophase Technologies Corporation
1319 Marquette Drive
Romeoville, IL 60446
Phone: +1-630-771-6700
Fax: +1-630-771-0825
Sales & Marketing +1-630-771-6709
Research Materials
Investor Relations +1-630-771-6708
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
| Related News Press |
News and information
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||